MedTrace Logo

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

NCT03015844 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-07-05

No results posted yet for this study

Summary

This is an expanded access protocol/compassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are not eligible for therapies of higher priority. Response rate, toxicity, and time to progression and death will be evaluated.

Conditions

Interventions

DRUG

131-I-meta-iodobenzylguanidine

Sponsors & Collaborators

  • Cohen Children's Medical Center

    collaborator OTHER

  • Northwell Health

    lead OTHER

Eligibility

Min Age
365 Days
Max Age
29 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03015844 on ClinicalTrials.gov